The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: A structured review of the literature

PharmacoEconomics

Volumn 25, Issue 11, 2007, Pages 913-933

  Fleurence, Rachael L ^a   Iglesias, Cynthia P ^b   Johnson, Jeanene M ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Alendronic acid, therapeutic use; Bisphosphonates, therapeutic use; Bone mineral density; Bone resorption; Cost effectiveness; Etidronic acid, therapeutic use; Fracture, prevention; Ibandronic acid, therapeutic use; Osteoporosis, prevention

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; HORMONE; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ABDOMINAL PAIN; ARTHRALGIA; BACKACHE; BONE DENSITY; CANADA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DENMARK; DIARRHEA; DRUG COST; DYSPEPSIA; FRAGILITY FRACTURE; GASTRITIS; GROUPS BY AGE; HEADACHE; HEALTH CARE SYSTEM; HEALTH SURVEY; HETEROTOPIC OSSIFICATION; HIGH RISK POPULATION; HUMAN; INFECTION; LEG CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCANDINAVIA; SCORING SYSTEM; SCREENING; SEX DIFFERENCE; SPAIN; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VERTEBRA FRACTURE;

EID: 35548986745     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725110-00003     Document Type: Review

References (84)

1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005; 16 Suppl. 2: S3-7
2. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992; 13 Suppl. 1: S7-S15
3. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis Int 1998; 8 (6): 611-7
4. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007 Mar; 22 (3): 465-75
5. Boonen S, Kaufman JM, Goemaere S, et al. The diagnosis and treatment of male osteoporosis: defining, assessing, and preventing skeletal fragility in men. Eur J Intern Med 2007; 18 (1): 6-17
6. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006; 443: 39-47
7. van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and Wales. Bone 2001; 29 (6): 517-22
8. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137 (9): 1001-5
9. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000; 54 Suppl. 1: 58-63
10. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol 1993; 7 (3): 459-77
11. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285 (6): 785-95
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33
13. Fleurence R, Iglesias CP, Torgerson D. Economic aspects of osteoporosis treatment. In: Cooper C, Lindsay R, editors. The prevention and treatment of osteoporosis in the high-risk patient. London: Martin Dunitz, 2005
14. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81 (8): 1047-53
15. Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997; 29 (1): 55-62
16. Red Book (™) for Windows®. Version 61129. Vol. 44. Greenwood Village (CO): Thomson PDR (CD Rom), 2007 Apr
17. British National Formulary [online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2007 Feb 07]
18. Fosamax® (alendronate sodium) [package insert]. Whitehouse Station (NJ): Merck & Co., Inc., 2006
19. Didronel® (etidronate disodium) [package insert]. Cincinnati (OH): Procter & Gamble Pharmaceuticals, Inc., 2005
20. Actonel® (risedronate sodium tablets) [package insert]. Cincinnati (OH): Procter & Gamble Pharmaceuticals, Inc., 2006
21. Boniva® (ibandronate sodium) [package insert]. Nutley (NJ): Roche Laboratories, Inc., 2006
22. Bondronat® (ibandronic sodium monohydrate) [package insert]. Welwyn Garden City: Roche Registration Limited, 2004
23. Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9 (22): 1-160
24. Luce BR, Mauskopf J, Sloan FA, et al. The return on investment in health care: from 1980 to 2000. Value Health 2006; 9 (3): 146-56
25. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323 (7324): 1300-3
26. Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002; 6 (29): 1-146
27. Coyle D, Cranney A, Lee KM, et al. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001; 19 (5 Pt 2): 565-75
28. Rodriguez Escolar C, Fidalgo Garcia ML, Rubio Cebrian S. A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture. Aten Primaria 1999; 24 (7): 390-6
29. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348 (9041): 1535-41
30. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280 (24): 2077-82
31. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001; 344 (5): 333-40
32. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282 (14): 1344-52
33. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91
34. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323 (2): 73-9
35. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322 (18): 1265-71
36. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12 (2): 140-51
37. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23 (4): 508-16
38. Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 2002; 31 (3): 659-79, xii
39. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporosis Int 2004; 15 (11): 862-71
40. Grima DT, Burge RT, Becker DL, et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002; 27 (9): 448-55
41. Hart WM, Rubio TC, Burrell A, et al. Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate [in Spanish]. Revista Espanola de Enfermedades Metabolicas Oseas 2002; 11 (3): 97-104
42. Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 1995; 34 (12): 1167-71
43. Johnell O, Jönsson B, Jönsson L, et al. Cost effectiveness of alendronate (fosamax®) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21 (5): 305-14
44. Aursnes I, Storvik G, Gasemyr J, et al. A Bayesian analysis of bisphosphonate effects and cost-effectiveness in post-menopausal osteoporosis. Pharmacoepidemiol Drug Saf 2000; 9 (6): 501-9
45. Rosner AJ, Grima DT, Torrance GW, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998; 14 (5): 559-73
46. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333 (22): 1437-43
47. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95 (6): 557-67
48. Montessori ML, Scheele WH, Netelenbos JC, et al. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int 1997; 7 (1): 52-8
49. Pacifici R, McMurtry C, Vered I, et al. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab 1988; 66 (4): 747-53
50. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104 (3): 219-26
51. Iglesias CP, Torgerson DJ, Bearne A, et al. The cost utility of bisphosphonate treatment in established osteoporosis. QJM Mon J Assoc Phys 2002; 95 (5): 305-11
52. Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006; 99 (2): 123-31
53. Schousboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142 (9): 734-41
54. Christensen PM, Brixen K, Gyrd HD, et al. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005; 96 (5): 387-96
55. Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for aminobisphosphonate therapy. Osteoporosis Int 2005; 16 (12): 1883-93
56. Borgström F, Johnell O, Jönsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004; 34 (6): 1064-71
57. Buckley LM, Hillner BE. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 2003; 30 (1): 132-8
58. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337 (6): 382-7
59. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339 (5): 292-9
60. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33 (4): 348-50
61. Mobley LR, Hoerger TJ, Wittenborn JS, et al. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Mak 2006; 26 (2): 194-206
62. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005; 53 (10): 1697-704
63. Solomon DH, Kuntz KM. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum 2000; 43 (9): 1967-75
64. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis Int 1996; 6 (4): 265-75
65. Brown MA, Bradlow J, Gray AM. Cost effectiveness of bone density measurements. J Br Menopause Soc 2001; 7 (3): 130-5
66. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85 (11): 4118-24
67. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997; 277 (14): 1159-64
68. Urdahl H, Manca A, Sculpher MJ. Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis. Pharmacoeconomics 2006; 24 (12): 1181-97
69. Brecht JG, Kruse HP, Mohrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004; 24 (1): 1-10
70. Brecht JG, Kruse HP, Felsenberg D, et al. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 2003; 23 (4): 93-105
71. Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 2003; 9 (2): 150-8
72. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporosis Int 2006; 17 (1): 29-40
73. Birks YF, Porthouse J, Addie C, et al. Randomized controlled trial of hip protectors among women living in the community. Osteoporosis Int 2004; 15 (9): 701-6
74. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365 (9471): 1621-8
75. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care [abstract]. BMJ 2005; 330 (7498): 1003
76. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293 (18): 2257-64
77. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332 (7543): 699-703
78. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative. A randomized trial. JAMA 2003; 289 (20): 2673-84
79. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291 (14): 1701-12
80. Grady D. Postmenopausal hormones: therapy for symptoms only. N Engl J Med 2003; 348 (19): 1835-7
81. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). A randomized trial. JAMA 2006; 296 (24): 2927-38
82. Coyle D, Tosteson AN. Towards a reference case for economic evaluation of osteoporosis treatments. J Rheumatol Suppl 2003; 68: 31-6
83. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003; 6 (1): 9-17
84. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461-77